Skip to content

Study on survival from prolonged cardiac arrest treated with an artificial blood pump (ECMO)

Survival outcomes in patients who have had prolonged cardiac arrest treated with artificial blood pump suppor

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615000779572
Acronym
2CHEER
Enrollment
25
Registered
2015-07-27
Start date
2015-08-03
Completion date
2018-06-01
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Only a few patients (less than 10%) survive cardiac arrest that lasts for more than 30 minutes, even if the cause is potentially reversible. ECMO is a blood pump that can be placed in large blood vessels in the groin and takes over the functions of the heart and lungs. This study will look at how many people survive persisting cardiac arrest when ECMO is used to support the heart until the cause of the cardiac arrest has been treated and the heart has had time to recover.

Interventions

Mechanical chest compressions with a Lucas Device, commenced either in-hospital (cardiac arrest team) or out-of-hospital (by paramedics) Induced hypothermia with 2L of intravenouse ice-cold saline, commenced by paramedics, Emergency Department or ICU staff. Peripheral veno-arterial ECMO support (by anaesthetists and surgeons) to facilitate early revascularisation (if indicated) by cardiologists. Neurological prognostication will be performed at 96 hours to determine limits of therapy. The ove

Mechanical chest compressions with a Lucas Device, commenced either in-hospital (cardiac arrest team) or out-of-hospital (by paramedics) Induced hypothermia with 2L of intravenouse ice-cold saline, commenced by paramedics, Emergency Department or ICU staff. Peripheral veno-arterial ECMO support (by anaesthetists and surgeons) to facilitate early revascularisation (if indicated) by cardiologists. Neurological prognostication will be performed at 96 hours to determine limits of therapy. The overall duration of ECMO support is anticipated to be approximately 2-5 days

Sponsors

A/Prof Paul Forrest
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
12 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

In-and out-of-hospital cardiac arrest, refractory to conventional ACLS Witnessed cardiac arrest Potentially reversible aetiology No major known co-morbidities

Exclusion criteria

Known major co-morbidities

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026